Roivant Sciences (ROIV) Financials

Roivant Sciences (ROIV) continues to burn cash in the near term, but the company shows a very large liquidity cushion and ongoing access to capital markets. In Q3 2025, revenue remained modest and operating costs dominated, resulting in a mid-to-high single-digit hundred million dollar quarterly loss. The balance sheet, however, shows a substantial equity base and a large pool of cash and short-term investments, providing a substantial runway if the company needs to fund ongoing development or operations.

Key trends observed across the most recent four years (through Q3 2025) include persistent operating losses relative to very small quarterly revenue, a cash flow profile that is negative from operations but supported by financing activity, and a strong balance-sheet position driven by equity capital and sizable cash and investments. The company’s liquidity position is notably robust, and financing activity has been a meaningful source of cash to fund ongoing activities. As with several biotech-adjacent or pharma-focused players, the core business appears to still be in a capital-intensive phase with no immediate accretion to profitability from quarterly results; capital markets remain a critical funding channel.

• Very strong liquidity position as of Q3 2025: Roivant reported cash and cash equivalents of about $1.48B and short-term investments around $3.05B, totaling roughly $4.53B in liquid assets, with total current assets near $4.66B. This provides a substantial cash runway relative to quarterly cash outflows.
• Substantial equity funding in Q3 2025: Issuance of common equity around $194M helped support financing activity, contributing to a net financing inflow of about $328M for the quarter. This reduces near-term liquidity risk but implies ongoing dilution risk for shareholders.
• Net cash from investing activities was modestly positive in Q3 2025: Net cash from investing activities totaled about $109.5M, driven by the sale/maturity of investments ($1.12B) partially offset by purchases ($1.013B). This provides some cushion aside from operating and financing cash flows.
• Revenue ticked up modestly in Q3 2025: Operating revenue was about $2.0M, up from the prior quarter’s levels, indicating a modest improvement in top-line activity even as profitability remains limited.
• Large equity cushion supports balance sheet: Total equity (including noncontrolling interests) sits near $4.97B, providing a substantial buffer against liabilities and supporting ongoing financing flexibility.
• Healthy current asset balance vs. current liabilities: Total current assets around $4.66B vs. total current liabilities of about $152M, indicating a strong liquidity and working-capital position on the balance sheet.
• High reported gross margin in some quarters: In several quarters, cost of revenue was very low or zero, resulting in near-100% gross margins on small revenue bases, though this reflects the timing and composition of costs rather than sustained product-level profitability.
• Shares outstanding in a wide range across quarters: Weighted-average shares outstanding hovered around 696–716 million across 2025 quarters, reflecting moderate to high dilution potential depending on future equity actions.

• Ongoing large operating losses: In Q3 2025, operating income was -$339.2M and net income attributable to common shareholders was -$265.9M, highlighting a continued lack of near-term profitability.
• Material negative cash flow from operations: Net cash from continuing operating activities was -$196.5M in Q3 2025 (and similarly negative in prior quarters), indicating ongoing cash burn from core activities.
• Substantial operating costs relative to revenue: SG&A (~$175.1M) and R&D (~$165.4M) in Q3 2025, plus other operating expenses, dwarf the quarterly revenue, amplifying the quarterly losses.
• Significant cumulative deficit on retained earnings: Retained earnings were deeply negative (e.g., around -$695M in Q3 2025), reflecting a long-standing cumulative deficit rather than profitability restoration.
• Reliance on external financing to fund operations: Substantial equity issuance and net financing inflows have been necessary to fund ongoing activities, underscoring reliance on capital markets for liquidity.